您的位置：首页 > 新闻中心 > 社会 > 正文

小时代

陕西省将抽取近1.4万户家庭未来五年记录每天收支_陕西调查总队_工作_我的网站

这个男人来自地球

一 | CVS Health is planning to remove one type of a common decongestant from shelves after an advisory committee to the U.S. Food and Drug Administration said it was ineffective earlier this year.The products contain the oral formulation of phenylephrine (PE), which is found in several over-the-counter (OTC) medications.Although PE has been used as a decongestant for nearly a century, experts have been questioning its efficacy for years.The FDA Nonprescription Drugs Advisory Committee unanimously voted in September that PE did not improve nasal congestion any more than a placebo at the dosage given for OTC use.In response, CVS said it is removing products, in which PE is the only active ingredient from store shelves. This means products like Dayquil, which used a combination of active ingredients, will remain available for purchase."We are aware of the FDA Advisory Committee's position on oral phenylephrine (PE) and will follow direction from the FDA to ensure products we sell comply with all laws and regulations," CVS Health said in a statement. "We are removing certain oral cough and cold products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores. Other oral cough and cold products will continue to be offered to meet consumer needs."CVS did not give specifies on brands that will be removed.The FDA told ABC News it has not yet determined whether it no longer considers PE to be a safe and effective medication and has not ordered the product to be removed from shelves. CVS's move is voluntary."The FDA has no further information to provide at this time regarding the timing of any decision the agency may make following the advisory committee meeting," the federal health agency said.The Consumer Healthcare Products Association told ABC News that the advisory committee's recommendation is a non-binding decision and not a change in regulation."FDA is currently in the process of reviewing the regulatory status of oral phenylephrine (PE) following September's advisory committee meeting," CHPA said in a statement. "Until FDA makes a determination on the committee's recommendation, oral PE remains a Category 1 OTC ingredient, which is generally recognized as safe and effective."Concerns were first raised about PE in 2007. Since then, evidence has accumulated showing that the drug offers little to no relief for nasal congestion.Experts believe this is because the body processes the drug before it reaches the nasal passages where it needs to work.It's unclear if other major retail pharmacy chains will follow in CVS's footsteps.Walgreens Boots Alliance would not disclose whether it was planning to remove products with PE from store shelves and said it would defer to the FDA."Walgreens follows FDA regulations. We are closely monitoring the situation and actively partnering with the Walgreens Office of Clinical Integrity and suppliers on appropriate next steps," a Walgreens spokesperson told ABC News.Other major pharmacy chains including Albertsons, Costco and Kroger did immediately reply to ABC News' request for comment. Walmart did not have an answer immediately available.ABC News' Sasha Pezenik and Sony Salzman contributed to this report.。

原标题：陕西省将抽取近1.4万户家庭未来五年记录每天收支华商报记者从国家统计局陕西调查总队获悉，9月，我省新一轮住户调查大样本轮换工作全面启动，涉及全省108个区、县（市）1334个调查小区，调查规模将达14万户城乡居民。

二 | 住户调查是我国一项非常重要的政府统计调查，通过政府统计调查员入户访问和居民记账的方式详细了解居民家庭收入、支出、居住环境等生活状况，为政府决策提供重要参考。调查获得的城乡居民人均可支配收入、消费等数据，是有关部门制定最低生活保障、最低工资、法律赔偿等标准的重要数据来源，是政府科学制定民生政策、评估政策效果的重要依据，对于扎实做好保障和改善民生各项工作，推进高质量发展，实现共同富裕，提升国家治理能力具有十分重要的意义。住户调查大样本轮换每五年进行一次，目的是防止住户调查样本老化、保证样本代表性，保障住户调查的数据质量。目前，住户调查大样本轮换工作已进入现场调查阶段，将于10月上旬完成入户摸底调查工作，10月至11月完成调查户落实和开户调查工作。调查结束后，将从14万户城乡居民中抽取近1.4万户家庭，于今年12月1日起作为未来五年调查周期的调查户，代表全省1343万户居民家庭“为国记账”，记录每天家庭收入和支出。华商报记者毛蜜娜返回搜狐，查看更多责任编辑：

。